Health Care [ 2/12 ] | Pharmaceuticals [ 26/74 ]
NASDAQ | Common Stock
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD).
In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist.
Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome.
Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE).
The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020.
Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 20, 25 | 1.08 Increased by +140.00% | 0.82 Increased by +32.17% |
| Oct 29, 24 | 0.79 Increased by +5.33% | 0.67 Increased by +17.91% |
| Aug 6, 24 | 0.20 Decreased by -64.29% | -0.06 Increased by +433.33% |
| Apr 30, 24 | 0.67 Increased by +1.52% | 0.60 Increased by +11.67% |
| Feb 22, 24 | 0.45 Decreased by -43.04% | 0.48 Decreased by -6.25% |
| Oct 31, 23 | 0.75 Decreased by -47.92% | 0.65 Increased by +15.38% |
| Aug 1, 23 | 0.56 Increased by +43.59% | 0.63 Decreased by -11.11% |
| May 2, 23 | 0.66 Increased by +29.41% | 0.47 Increased by +40.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 201.27 M Increased by +19.51% | 49.48 M Increased by +85.95% | Increased by +24.58% Increased by +55.59% |
| Sep 30, 24 | 186.04 M Increased by +16.08% | 46.09 M Increased by +19.84% | Increased by +24.78% Increased by +3.24% |
| Jun 30, 24 | 172.81 M Increased by +28.76% | 11.59 M Decreased by -66.21% | Increased by +6.71% Decreased by -73.75% |
| Mar 31, 24 | 154.62 M Increased by +29.79% | 38.33 M Increased by +30.01% | Increased by +24.79% Increased by +0.17% |
| Dec 31, 23 | 168.41 M Increased by +31.26% | 26.61 M Decreased by -45.15% | Increased by +15.80% Decreased by -58.21% |
| Sep 30, 23 | 160.27 M Increased by +36.74% | 38.46 M Decreased by -56.27% | Increased by +24.00% Decreased by -68.02% |
| Jun 30, 23 | 134.22 M Increased by +25.40% | 34.30 M Increased by +45.77% | Increased by +25.56% Increased by +16.24% |
| Mar 31, 23 | 119.13 M Increased by +39.63% | 29.48 M Increased by +37.24% | Increased by +24.75% Decreased by -1.72% |
This website uses cookies. To learn more about cookies, please see our privacy policy .